High-risk screening for Gaucher disease in patients with neurological symptoms
- PMID: 29602947
- DOI: 10.1038/s10038-018-0438-7
High-risk screening for Gaucher disease in patients with neurological symptoms
Abstract
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by the deficiency of glucocerebrosidase enzyme activity. Clinical phenotypes of GD are categorized into three groups: (i) non-neuronopathic GD (type 1), (ii) acute neuronopathic GD (type 2) and (iii) subacute neuronopathic GD (type 3). The high-risk screening of neuronopathic GD has been performed using an enzymatic assay on the dried blood spot (DBS) samples. We enrolled a total of 102 individuals (47 females, 55 males; 0-57 years old; median age 10.5 years) with various neurological symptoms. We detected two patients with very low enzyme activity and they were diagnosed with the disease by using glucocerebrosidase gene analysis. Patient 1 was found to be compound heterozygous for the p.R159W/p.R170C locus and patient 2 was found to harbor two mutations at the IVS7+1G>T (c.999+1G>T) and p.L483P sites. This simple screening protocol using DBS samples is useful for early diagnosis of GD in high-risk and underdiagnosed patients suffering from various neurological symptoms.
Similar articles
-
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?Int J Mol Sci. 2022 Jan 30;23(3):1627. doi: 10.3390/ijms23031627. Int J Mol Sci. 2022. PMID: 35163551 Free PMC article.
-
High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified.Clin Chim Acta. 2020 Jul;506:22-27. doi: 10.1016/j.cca.2020.03.016. Epub 2020 Mar 9. Clin Chim Acta. 2020. PMID: 32165122
-
Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients.Orphanet J Rare Dis. 2021 Dec 20;16(1):519. doi: 10.1186/s13023-021-02151-2. Orphanet J Rare Dis. 2021. PMID: 34930372 Free PMC article.
-
Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.Mol Genet Metab. 2021 Feb;132(2):49-58. doi: 10.1016/j.ymgme.2021.01.002. Epub 2021 Jan 9. Mol Genet Metab. 2021. PMID: 33483255 Free PMC article. Review.
-
Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.Blood Cells Mol Dis. 2011 Jan 15;46(1):75-84. doi: 10.1016/j.bcmd.2010.08.012. Epub 2010 Sep 28. Blood Cells Mol Dis. 2011. PMID: 20880730 Free PMC article. Review.
Cited by
-
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.Acta Neurol Belg. 2024 Aug;124(4):1213-1223. doi: 10.1007/s13760-024-02493-1. Epub 2024 Feb 28. Acta Neurol Belg. 2024. PMID: 38413480 Review.
-
Newborn screening for Gaucher disease in Japan.Mol Genet Metab Rep. 2022 Feb 18;31:100850. doi: 10.1016/j.ymgmr.2022.100850. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35242582 Free PMC article.
-
Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey.Intern Med. 2021;60(5):699-707. doi: 10.2169/internalmedicine.5064-20. Epub 2021 Mar 1. Intern Med. 2021. PMID: 33642560 Free PMC article.
-
Pitfalls in the diagnosis of Gaucher disease in Iraq: A diagnostic experience from a developing country.Pak J Med Sci. 2021 May-Jun;37(3):782-787. doi: 10.12669/pjms.37.3.2930. Pak J Med Sci. 2021. PMID: 34104165 Free PMC article.
-
High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations.J Hum Genet. 2019 Sep;64(9):891-898. doi: 10.1038/s10038-019-0633-1. Epub 2019 Jun 19. J Hum Genet. 2019. PMID: 31213654 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical